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Summary The role of cholecystokinin (CCK) has been explored in pancreatic carcinogenesis following
pancreatobiliary diversion (PBD), using the specific CCK receptor antagonist CR-1409. Male Wistar rats
(n = 80) weighing 70-100 g were given weekly i.p. injections of azaserine (30mg kg-' week-') for 3 con-
secutive weeks. One week later animals were randomised to receive either PBD or sham PBD and thereafter to
receive s.c. injections of either saline or CR-1409 (10mgkg-'day-', 5 days a week). Six months after
operation surviving rats were killed as follows: sham+saline 20, PBD+saline 19, sham+CR-1409 14,
PBD + CR-1409 11. Cardiac blood was taken for CCK assay and the pancreas was excised for wet weight
measurement and quantitative estimation of atypical acinar cell foci (AACF), the precursor of carcinoma.
PBD reduced median body weight (3-20% less than shams) but trebled the absolute and relative pancreatic
weights (P<0.001). CR-1409 blunted this adaptive response to PBD, reducing absolute pancreatic weight by
35% (P<0.005). PBD quadrupled circulating CCK concentrations, regardless of the antagonist treatment.
Acidophilic AACF occurred only in rats with PBD. CR-1409 markedly reduced the number of observed
acidophilic AACF by 90% (P<0.001) and the number of foci per pancreas by 93% (P<0.001). Moreover,
CR-1409 reduced the mean focal diameter of each lesion by 18% (P<0.005), the mean focal volume by 58%
(P<0.05) and the percentage of pancreas occupied by acidophilic foci by 95% (P<0.001). PBD enhances
pancreatic carcinogenesis by causing hypercholecystokininaemia, and CR-1409 largely inhibits this enhance-
ment.
The growth of experimental pancreatic tumours is regulated
by several hormones and growth factors, not only gastro-
intestinal peptides (Townsend et al., 1989), but also sex
hormones (Longnecker & Sumi, 1990), luteinising hormone-
releasing hormone (LHRH) (Redding & Schally, 1984),
glucocorticoids (Benz et al., 1986) and epidermal growth
factor (Malt et al., 1987). Among the gastrointestinal pep-
tides, cholecystokinin (CCK) and its analogues are of partic-
ular importance. In the rat and hamster, exogenous CCK
and the related substance caerulein stimulate maximal pan-
creatic secretion and pancreatic growth when administered
s.c. for 6 weeks (Barrowman & Mayston, 1974; Dembinski &
Johnson, 1980). Measures designed to increase circulating
CCK levels, such as dietary administration of trypsin inhib-
itors or injections of cholecystokinin, appear to enhance
pancreatic carcinogenesis in azaserine-treated rats (Lhoste et
al., 1988; Douglas et al., 1989), but similar studies in ham-
sters have given inconsistent results (Andren-Sandberg et al.,
1984; Howatson & Carter, 1985; Pour et al., 1988).
Diversion of bile and pancreatic secretions to the mid
small bowel causes pancreatic hyperplasia in rats (Miazzi et
al., 1987; Watanapa et al., 1991). The associated hyper-
cholecystokininaemia plus the inhibitory effect of the CCK
anatagonist CR-1409 indicate the pivotal role of CCK in the
adaptive response to pancreatobiliary diversion (PBD)
(Watanapa et al., 1991). Our long-term study in rats showed
that both PBD and massive small bowel resection will stimu-
late pancreatic growth, but only PBD enhances pancreatic
carcinogenesis (Stewart et al., 1991); CCK levels were not
measured in this experiment.
The present study was designed to test the hypothesis that
hypercholecystokininaemia explains the enhancing effect of
PBD on pancreatic carcinogenesis induced by azaserine in
rats. We used quantitative estimation of atypical acinar cell
foci (AACF) as the index of neoplastic change, in line with
others (Roebuck et al., 1984; Sumi et al., 1989), and the
specific CCK antagonist CR-1409 to inhibit the response.
Methods
Animal design
Male Wistar rats (n = 80) aged 4 weeks and weighing 70-
100 g were housed in groups of eight and later of five in
animal quarters with a 12 h day/night cycle. Standard
pelleted rat food (Paterson and the Christopher Hill Group,
Porton - diet PRD) and water were freely available. After 1
week ofacclimatisation, all animals received weekly i.p. injec-
tions of azaserine for 3 weeks (see below). One week after the
end of this course, animals were randomised to receive either
pancreatobiliary diversion (PBD) or sham PBD, comprising
triple small bowel transection and resuture. PBD involved
transposition of 50 cm proximal small bowel to lie between
the pylorus and duodenal papilla, whereas in shams the small
bowel was divided immediately distal to the pylorus, at the
duodenojejunal junction and again at the level of the mid-
small bowel. Operations were carried out under light ether
anaesthesia. A continuous 6/0 silk suture was used for anas-
tomoses.
Immediately after the operation, half the animals in each
group were further randomised to receive either CR-1409
(10 mg kg-' day-') or saline (2.5 ml kg-') by daily sub-
cutaneous injection, 5 days per week. CR-1409 was dissolved
in distilled water and brought to pH 9 by 0.01 N NaOH to
give a 0.4% solution. Food was reintroduced 12 h post-
operatively. Six months after operation, blood samples for
CCK assay were obtained by direct cardiac puncture after
overnight fasting; rats were then killed by exsanguination.
The pancreas was excised and trimmed free of adherent fat
and lymph nodes. The wet weight ofeach gland was recorded
before fixation in 10% buffered neutral formalin. Before
immersion in the fixative solution, each pancreas was spread
out on a piece of porous paper to ensure the maximal
transectional area for subsequent sectioning.
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Carcinogen
Azaserine (Sigma Chemical Company, UK) was dissolved in
0.9% NaCl and was administered by weekly i.p. injection
into each rat for 3 consecutive weeks. The dosage regime was
30mgkg-'week-', giving a total dose of 90mgkg1'.
CCK assay
Plasma CCK peptides were extracted from cardiac blood
samples with C18 'SepPak' (Waters, Harrow, UK) (Eysellein
et al., 1987), and the eluates were dried by centrifugal
evaporation (Savant, Farmingdale, NY, USA). CCK was
measured by a specific radioimmunoassay based on anti-
serum A2, raised by immunising a rabbit with natural porcine
CCK-33 (donated by Professors V. Mutt and S.R. Bloom).
Antiserum A2 (1:60,000) was incubated at 4°C for 3 days
with standard CCK-8 or with plama samples plus CCK-8
tracer labelled with '25iodine (1,000 c.p.m., Amersham, UK)
in 0.05 mol h' sodium phosphate buffer (pH 7.4) containing
0.25% gelatin and 0.01% mol l' EDTA. Free and bound
tracer were separated by the addition of 6% (weight/volume)
dextran. The concentrations of pure peptides that produced
half-maximal inhibition of binding of tracer to A2 were
2.0 pmol l1 for CCK-8, 2.4 pmol 1- for CCK-33 and
2.2 nmol 1' for gastrin 17. The coefficient of variation within
assays was 8.2% and between assays 12.8%. The sensitivity
of the assay (defined as minimal amount of CCK-8 that
could be distinguished from zero with 95% confidence) was
0.2 pmol, and the recovery of CCK-8 and CCK-33 through
the SepPak and assay procedure was 79%.
Quantitative estimation ofAACF
Histological sections (5 tm) of the whole pancreas were
stained with haematoxylin and eosin, coded and scrutinised
'blind' by light microscopy. The two observers evaluated
each section together and did not know what treatment each
animal had received. The atypical acinar cell foci (AACF)
were readily identified and classified as acidophilic or baso-
philic according to established criteria (Rao et al., 1982). The
total area of exocrine pancreatic tissue was measured directly
in a single histological secion from each pancreas by means
of a VIDS III video image analyser (Analytical Measuring
Systems, Cambridge). The same instrument was used to
count acidophilic and basophilic AACF and to measure their
transectional area. Data were processed numerically by the
Volugen computer package (InfoResearch Int., Bristol), using
an algorithm based on that of Campbell et al. (1982) and
modified by Pugh et al. (1983). The actual numerical lower
limits adopted were 0.0005 mm2 for basophilic AACF and
0.01 mm2 for the acidophilic variety; these values correspond
to those chosen by Roebuck et al. (1984). Details of this
analysis have been already described in our previous studies
(Stewart et al., 1991).
Statistical analysis
Student's t-test for unpaired data was used for the group
analysis of plasma CCK concentrations, since the data were
normally distributed. The levels were expressed as means
(s.e.m.). Median values and ranges were quoted for body
weight, pancreatic weight and quantitative estimation of
AACF. Statistical analysis of these parameters was per-
formed using Kruskal-Wallis analysis of variance and the
Mann-Whitney U-test.
Results
Mortality, body weight andpancreatic weight (Table I)
There are five early deaths from anaesthetic overdose or
anastomotic leakage, one in a sham + CR-1409 rat and four
in PBD + CR-1409 rats. Eleven rats died prematurely from
instestinal obstruction or extensive granuloma formation,
related either to anastomotic leakage or to repeated i.p.
injections: one in the PBD + saline group, five in the sham +
CR-1409 group and five in the PBD + CR-1409 group.
Yields ofhealthy survivors were as follows: sham + saline 20,
PBD + saline 19, sham + CR-1409 14 and PBD + CR-1409
11.
The median body weight of PBD rats was 3-20% less
than shams, although the reduction was only significant in
the CR-1409 treated groups. Likewise, animals receiving CR-
1409 weighed a median 5-22% less than their saline-treated
counterparts. Median pancreatic weight was markedly in-
creased by PBD, both absolute weight, which was 173%
greater, and relative weight (mg pancreas/100 g body weight),
which was 206% greater. The CCK antagonist CR-1409 had
differential effects in shams and rats with PBD. In shams it
caused modest elevations in pancreatic weight of 38-48%.
By contrast, CR-1409 partly inhibited the growth response to
PBD, reducing absolute pancreatic weight by 35%, although
these rats still had pancreata that were 30-62% heavier than
those of their sham counterparts.
The pancreata in several sham and some PBD animals
receiving CR-1409 showed extensive degeneration as charac-
terised by patchy necrosis, cellular infiltration and fibrosis.
Some pancreatic acinar cells also showed cytoplasmic vacu-
oles and loss of zymogen granules. These findings were not
seen in the saline-treated rats.
Plasma cholecystokinin (Table II)
There was a 4-fold increase in circulating CCK levels 6
months after PBD. Administration of CR-1409 had no
appreciable effect on plasma hormone levels.
Quantiative analysis ofAACF
Acidophilic AACF, the putative precancerous lesions, were
only seen in rats receiving PBD (Table III). CR-1409 sub-
stantially reduced the observed transectional data, so that the
number of AACF per cm2 pancreas was only one tenth of
those seen in controls given saline. Quantitative stereological
analysis of tissue sections confirmed the inhibitory effect of
CR-1409. Thus the number of acidophilic AACF per cm3 of
pancreas was markedly reduced (3.00 vs 33.93), as was the
total number of lesions per pancreas (5.73 vs 77.10). The
median diameter of each focus was 18% less and the volume
was 58% less. Consequently CR-1409 reduced the percentage
of the pancreatic volume occupied by acidophilic foci from
2.54% to 0.12%.
Table I Body weight, absolute and relative pancreatic weight
Sham + saline Sham + CR-1409 PBD + saline PBD + CR-1409
(n = 20) (n = 14) (n = 19) (n = 11)
Body weight (g) 523.1 483.Oe 516.0 40b
(440.0-551.0) (303.0-547.0) (310.0-563.0) (275.0-576.0) Absolute pancreatic weight (mg) 882.0 1165.0a 2310.0ad'510.0b
(750.0-1100.0) (950.0-1650.0) (1250.0-3850.0) (950.0-2400.0) Relative pancreatic weight 168.6 246.6a 509.8a 398.4c
(mg/100 g body weight) (143.1-206.4) (192.7-320.4) (241.3-808.2) (260.4-583.3)
Values are median (range). Significance vs sham + saline group: ap< 0.001; ep< 0.05. Significance vs sham + CR-1409
group: bp<0.05; cP<0.001. Significance vs PBD + saline group: dp<0.05.ROLE OF CCK IN PANCREATIC CARCINOGENESIS 665
Table II Plasma cholecystokinin concentration (pmol 1-) in rats with pancreatobiliary
diversion (PBD) or sham PBD
Sham + saline Sham + CR-1409 PBD + saline PBD + CR-1409
(n =20) (n = 14) (n = 19) (n = 11)
Plasma CCK 1.81 (0.13) 2.93 (0.43) 8.23 (0.87)8 10.95 (1.16)a
(pmol 1-)
Values are means (s.e.m.). Significance vs corresponding sham group: ap<0.001.
Table III Quantitative analysis ofacidophilic atypical acinarcell foci (AACF) in the pancreas ofazaserine-treated rats with
pancreatobiliary diversion (PBD) or sham PBD
Sham + saline Sham + CR-1409 PBD + saline PBD + CR-1409
(n =20) (n = 14) (n = 19) (n = 11)
No. of AACF cm-2 0.00 0.00 3.44a do.34a
(0.69-11.47) (0.00-3.03)
No. of AACFcm3 0.00 0.00 33.93a d3.00a
(6.56-117.32) (0.00-34.61)
No. of AACF/pancreas 0.00 0.00 77.10a d5.738
(10.50-352.95) (0.00-60.56)
Mean focal diameter (tm) 0.00 0.00 1064.80a C871.00a
(719.90-1637.00) (0.00-1207.74)
Mean focal volume (mm3 x 100) 0.00 0.00 51.45a b2l.79a
(13.20- 173.11) (0.00-62.84)
Volume as % ofpancreas 0.00 0.00 2.54a do.82a
(0.25-6.60) (0.00-1.13)
Values are medians (range). Only foci that are larger than 0.01 mm2 are counted. Significance vs sham + saline group:
ap<0.001. Significance vs PBD + saline group: bp<0.05; cp<0.005; dp<0.001.
By contrast, basophilic AACF occurred mainly in the sham
animals (Table IV), and the CCK antagonist had no consis-
tent effect on their development. Although saline-treated rats
had more lesions than those receiving CR-1409, the size of
each focus was smaller, so that a similar percentage of the
pancreas was occupied by basophilic foci.
Discussion
Our data confirm the potent effect of pancreatobiliary diver-
sion in enhancing experimental pancreatic carcinogenesis and
strongly support the hypothesis that hyperchlecystokinin-
aemia is the key intermediary (Miazza et al., 1987; Stewart et
al., 1991; Watanapa et al., 1991). Not only were circulating
CCK levels elevated after PBD, but in addition the specific
antagonist CR-1409 sharply diminished the number of acido-
philic AACF. These foci are now well established as the
precursors of pancreatic carcinoma in this model, whereas
basophilic foci appear to be of little importance. The
acidophilic foci show considerable growth potential with a
mitotic index (2.75) which greatly exceeds that of basophilic
foci (0.125) or normal pancreas (zero) (Scarpelli et al., 1984).
Using [3H] thymidine incorporation and autoradiography,
Rao and colleagues (1982) demonstrated much greater pro-
liferative capacity of cells in acidophilic foci than basophilic
foci (23.2 vs 1.2 labelled nuclei per 1,000 cells). Although
fewer than 1% of these acidophilic AACF progress to
become neoplasms (Longnecker et al., 1979), the number and
size of acidophilic AACF seem to correlate positively with
the incidence of carcinoma (Roebuck & Longnecker, 1977;
Longnecker et al., 1981).
The finding that PBD increases pancreatic weight as well
as promoting carcinogenesis suggests that in the pancreas, as
in the large intestine (Bristol et al., 1984), hyperplasia pre-
cedes and predisposes to neoplasia. Measurements of relative
and absolute wet weights are relatively crude indices of pan-
creatic adaptation, but the necessity of measuring AACF
precluded any more sophisticated tests in the present experi-
ment. We have previously shown that PBD causes pancreatic
hyperplasia, with increased contents of RNA and DNA and
increased cytokinetic indices 4 to 14 days after operation
(Watanapa et al., 1991). As in the present experiment, CR-
1409 inhibited the growth-promoting effect of PBD without
Table IV Quantitative analysis ofbasophilic atypical acinar cell foci (AACF) in the pancreas ofazaserine-treated rats with
pancreatobiliary diversion (PBD) or sham PBD
Sham + saline Sham + CR-1409 PBD + saline PBD + CR-1409
(n=20) (n= 14) (n = 19) (n= 11)
No. of AACFcm-2 1.42 1.16 0.00a cC.00a
(0.38-6.60) (0.00-3.93) (0.00-0.41) (0.00-0.24)
No. of AACFcm-3 43.10 28.26 0.00a c.000a
(11.81 -246.66) (0.00-93.23) (0.00-11.91) (0.00-9.01)
No. of AACF/pancreas 34.50 31.15 0.00a c0.00a
(11.22-184.99) (0.00-104.42) (0.00-36.16) (0.00-13.61)
Mean focal diameter (Jm) 327.24 394.10 0.00a b8.00a
(268.22-434.58) (0.00-709.07) (0.00-379.93) (0.00-467.91)
Mean focal volume (mm3 x 100) 1.33 2.24 0.00a b8.00a
(0.54-2.91) (0.00- 19.77) (0.00-2.68) (0.00-3.77)
Volume as % of pancreas 0.08 0.07 0.00a c0.00a
(0.01-0.32) (0.00-0.36) (0.00-0.03) (0.00-0.02)
Values are medians (range). Only foci that are larger than 0.0005 mm2 are counted. Significance vs sham + saline group:
'P<0.001. Significance vs CR-1409 group: bp<0.05; cP<0.005.666 P. WATANAPA et al.
affecting plasma CCK levels, showing that the drug probably
acts as a receptor antagonist (Leung et al., 1986). Our
preliminary ultrastructural data indicate that CR-1409 causes
marked vacuolation in the cytoplasm of pancreatic acinar
cells, suggesting a direct toxic effect (Sarraf et al., 1990). The
inflammatory changes seen in shams with CR-1409 may ex-
plain the increased pancreatic weight in these animals, while
in rats with PBD this effect was overcome by the growth
stimulatory response. In line with Douglas and colleagues
(1989), our finding that CR-1409 reduced both pancreatic
weight and the number of AACF supports the association
between hyperplasia and neoplasia. To the contrary, one
stimulus (massive enterectomy) can cause pancreatic growth
without promoting cancer (Stewart et al., 1991), while
another (exogenous caerulein) can cause the reverse (Lhoste
& Longnecker, 1987). Thus the co-carcinogenic effect ofPBD
might be partly independent of its growth-promoting effect
and could reflect a direct action of CCK on malignant trans-
formation of the exocrine pancreas.
The development of AACF is influenced by the age of the
rats at the onset of treatment (Longnecker et al., 1977). The
low yield rate of acidophilic AACF in this experiment may
reflect the greater age of animals used compared to other
studies (4 weeks vs 19 days and 14 days) (Roebuck et al.,
1985; Douglas et al., 1989). Among saline-treated animals,
the increased yield of basophilic foci in controls (as opposed
to those with PBD) is of doubtful relevance since most
modulators of the postinitiation phase of pancreatic car-
cinogenesis have little effect on these lesions (Roebuck et al.,
1985).
There are two possible explanations for the hypercholecy-
stokininaemia that follows PBD (Miazza et al., 1987; Watan-
apa et al., 1991): (1) increased CCK secretion, as diversion of
pancreatobiliary secretions away from the transposed jejun-
um suppresses the normal negative feedback mechanism and
(2) increased CCK synthesis, if the jejunal hyperplasia that
follows PBD (Miazza et al., 1982; Hosomi et al., 1987)
involves the enteroendocrine cells. We have previously found
2-fold elevations in circulating CCK 7-14 days after PBD
(Watanapa et al., 1991), and we now find 4-fold elevations 6
months later. The progressive rise in CCK may argue more
for an increased synthesis of the hormone than for perpetual
interruption of feedback inhibition.
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